BLU
BELLUS Health Inc. [BLU] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BLU Stock Summary
In the News
BLU Financial details
Company Rating
Neutral
Market Cap
1.87B
Income
-108.19M
Revenue
3.17B
Book val./share
2.92
Cash/share
1.89
Dividend
-
Dividend %
-
Employees
74
Optionable
No
Shortable
Yes
Earnings
08 Aug 2023
P/E
-21.51
Forward P/E
-
PEG
5.15
P/S
124656.2
P/B
5.06
P/C
-
P/FCF
-20.96
Quick Ratio
32.13
Current Ratio
33.42
Debt / Equity
0.04
LT Debt / Equity
0.04
-
-
EPS (TTM)
-0.52
EPS next Y
-
EPS next Q
-
EPS this Y
-26.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
29.67%
Revenue last 5Y
-9.04%
Revenue Q/Q
8.47%
EPS Q/Q
103.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.37%
Inst Trans
0%
ROA
-23%
ROE
-24%
ROC
-0.24%
Gross Margin
100%
Oper. Margin
-602047%
Profit Margin
-578587%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.38-14.76
52W High
-
52W Low
-
RSI
-
Rel Volume
0.53
Avg Volume
5.38M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-0.27898
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
BLU Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.18 | -0.09 | -0.54 | -0.9 | -0.66 | |
| Operating cash flow per share | -0.22 | -0.07 | -0.5 | -0.77 | -0.67 | |
| Free cash flow per share | -0.22 | -0.09 | -0.51 | -0.88 | -0.85 | |
| Cash per share | 1.07 | 0.3 | 1.66 | 3.14 | 2.92 | |
| Book value per share | 1.1 | 0.3 | 2.49 | 3.68 | 3.39 | |
| Tangible book value per share | 1.05 | 0.11 | 0.75 | 2.39 | 2.47 | |
| Share holders equity per share | 1.1 | 0.3 | 2.49 | 3.68 | 3.39 | |
| Interest debt per share | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Market cap | 127.29M | 2.93B | 180.61M | 638.49M | 948.25M | |
| Enterprise value | 116.33M | 2.91B | 132.23M | 489.29M | 862.28M | |
| P/E ratio | -21 | -110.78 | -5.68 | -8.96 | -12.46 | |
| Price to sales ratio | 4.95K | 109.19K | 12.04K | 39.91K | 59.27K | |
| POCF ratio | -17.04 | -137.15 | -6.07 | -10.43 | -12.3 | |
| PFCF ratio | -17.04 | -116.62 | -5.96 | -9.18 | -9.68 | |
| P/B Ratio | 3.43 | 33.15 | 1.23 | 2.19 | 2.43 | |
| PTB ratio | 3.43 | 33.15 | 1.23 | 2.19 | 2.43 | |
| EV to sales | 4.53K | 108.51K | 8.82K | 30.58K | 53.89K | |
| Enterprise value over EBITDA | -16.74 | -117.13 | -4.17 | -6.72 | -11.85 | |
| EV to operating cash flow | -15.57 | -136.28 | -4.45 | -7.99 | -11.18 | |
| EV to free cash flow | -15.57 | -115.88 | -4.37 | -7.04 | -8.8 | |
| Earnings yield | -0.05 | -0.01 | -0.18 | -0.11 | -0.08 | |
| Free cash flow yield | -0.06 | -0.01 | -0.17 | -0.11 | -0.1 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.58 | 0.74 | 1.53 | 2.05 | 1.18 | |
| Current ratio | 18.73 | 12.38 | 18.11 | 15.23 | 22.42 | |
| Interest coverage | -1.98K | -1.14K | -844.67 | -1.33K | -998.5 | |
| Income quality | 1.12 | 0.81 | 0.94 | 0.86 | 1.01 | |
| Dividend Yield | 0 | 0 | 0.05 | 0 | 0 | |
| Payout ratio | 0 | -0.04 | -0.27 | 0 | 0 | |
| Sales general and administrative to revenue | 97.4 | 249.32 | 649 | 891.44 | 1.22K | |
| Research and developement to revenue | 205.29 | 746.28 | 1.58K | 3.74K | 3.68K | |
| Intangibles to total assets | 0.04 | 0.02 | 0.33 | 0.16 | 0.12 | |
| Capex to operating cash flow | 0 | 0.18 | 0.02 | 0.14 | 0.27 | |
| Capex to revenue | 0 | -140.16 | -35.67 | -518.77 | -1.31K | |
| Capex to depreciation | 0 | -31.05 | -2.99 | -43.01 | -68.48 | |
| Stock based compensation to revenue | 19.97 | 60.97 | 319.4 | 397.06 | 651.25 | |
| Graham number | 2.12 | 0.78 | 5.5 | 8.62 | 7.09 | |
| ROIC | -0.18 | -0.29 | -0.22 | -0.25 | -0.2 | |
| Return on tangible assets | -0.16 | -0.28 | -0.31 | -0.27 | -0.21 | |
| Graham Net | 1.02 | 0.22 | 1.58 | 2.93 | 2.79 | |
| Working capital | 35.35M | 86.15M | 96.66M | 241.26M | 340.02M | |
| Tangible asset value | 35.41M | 86.44M | 97.02M | 241.93M | 340.91M | |
| Net current asset value | 35.35M | 86.13M | 96.32M | 240.64M | 339.09M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 972.13K | 932K | 1.16M | 1.21M | 1.51M | |
| Average payables | 394.2K | 2.18M | 2.3M | 1.75M | 3.7M | |
| Average inventory | 0 | -17.11M | -17.11M | 1.5 | 1.5 | |
| Days sales outstanding | 8.44K | 17.3K | 25.53K | 31.23K | 37.48K | |
| Days payables outstanding | 0 | 1.45 | 0.17 | 0.47 | 0.47 | |
| Days of inventory on hand | 0 | -12.56 | 0 | 0 | 0 | |
| Receivables turnover | 0.04 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Payables turnover | 0 | 251.57 | 2.21K | 777.73 | 774.17 | |
| Inventory turnover | 0 | -29.06 | 1.43B | 1.11B | 3.51B | |
| ROE | -0.16 | -0.3 | -0.22 | -0.24 | -0.19 | |
| Capex per share | 0 | -0.01 | -0.01 | -0.1 | -0.18 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 3.71 | 4.07 | |
| Net income per share | -0.2 | -0.16 | -0.2 | -0.05 | -0.11 | |
| Operating cash flow per share | -0.15 | -0.27 | -0.21 | -0.07 | -0.04 | |
| Free cash flow per share | -0.19 | -0.31 | -0.25 | -0.08 | -0.06 | |
| Cash per share | 2.99 | 2.92 | 2.47 | 1.87 | 1.89 | |
| Book value per share | 3.34 | 3.39 | 2.91 | 2.84 | 2.92 | |
| Tangible book value per share | 2.46 | 2.47 | 1.86 | 2.33 | 2.4 | |
| Share holders equity per share | 3.34 | 3.39 | 2.91 | 2.84 | 2.92 | |
| Interest debt per share | 0.01 | 0.01 | 0.01 | 0.12 | 0.12 | |
| Market cap | 1.29B | 948.25M | 911.39M | 6.05B | 5.98B | |
| Enterprise value | 1.21B | 862.28M | 827.21M | 5.8B | 5.75B | |
| P/E ratio | -13.02 | -12.99 | -9.09 | -68.15 | -35.02 | |
| Price to sales ratio | 321.56K | 237.06K | 303.8K | 3.97 | 3.62 | |
| POCF ratio | -71.25 | -30.86 | -33.63 | -215.32 | -338.28 | |
| PFCF ratio | -56.43 | -26.75 | -28.37 | -180.48 | -257.45 | |
| P/B Ratio | 3.16 | 2.43 | 2.47 | 5.19 | 5.05 | |
| PTB ratio | 3.16 | 2.43 | 2.47 | 5.19 | 5.05 | |
| EV to sales | 303.49K | 215.57K | 275.74K | 3.81 | 3.48 | |
| Enterprise value over EBITDA | -57.42 | -45.25 | -33.08 | -179.99 | -97.01 | |
| EV to operating cash flow | -67.24 | -28.06 | -30.52 | -206.32 | -325.35 | |
| EV to free cash flow | -53.26 | -24.32 | -25.75 | -172.93 | -247.61 | |
| Earnings yield | -0.02 | -0.02 | -0.03 | 0 | -0.01 | |
| Free cash flow yield | -0.02 | -0.04 | -0.04 | -0.01 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0.04 | 0.04 | |
| Debt to assets | 0 | 0 | 0 | 0.02 | 0.02 | |
| Net debt to EBITDA | 3.42 | 4.51 | 3.37 | 7.86 | 3.86 | |
| Current ratio | 16.96 | 22.42 | 33.42 | 1.5 | 1.5 | |
| Interest coverage | -887.5 | -942.3 | -1.39K | 0 | 0 | |
| Income quality | 0.73 | 1.68 | 1.08 | 1.27 | 0.41 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.46K | 1.06K | 1.8K | 0.07 | 0.06 | |
| Research and developement to revenue | 4.34K | 4.39K | 7.47K | 0 | 0 | |
| Intangibles to total assets | 0.12 | 0.12 | 0.13 | 0.07 | 0.07 | |
| Capex to operating cash flow | 0.26 | 0.15 | 0.19 | 0.19 | 0.31 | |
| Capex to revenue | -1.19K | -1.18K | -1.67K | 0 | 0 | |
| Capex to depreciation | -65.85 | -53.08 | -48.3 | -0.74 | -0.77 | |
| Stock based compensation to revenue | 741.25 | 623.75 | 977.33 | 0.02 | 0.02 | |
| Graham number | 3.9 | 3.47 | 3.6 | 1.86 | 2.63 | |
| ROIC | -0.06 | -0.06 | -0.07 | -0.03 | -0.06 | |
| Return on tangible assets | -0.07 | -0.05 | -0.08 | -0.01 | -0.01 | |
| Graham Net | 2.81 | 2.79 | 2.4 | 0.55 | 0.56 | |
| Working capital | 355.81M | 340.02M | 317.91M | 904.12M | 890.08M | |
| Tangible asset value | 356.54M | 340.91M | 318.8M | 957.94M | 973.26M | |
| Net current asset value | 355.44M | 339.09M | 317.07M | 756.91M | 747.26M | |
| Invested capital | 0 | 0 | 0 | 0.04 | 0.04 | |
| Average receivables | 1.49M | 1.44M | 1.84M | 939.63M | 1.85B | |
| Average payables | 20.45M | 13.3M | 6.99M | 175.49M | 368.1M | |
| Average inventory | 1 | 1.5 | 1 | 1.5 | 1.5 | |
| Days sales outstanding | 27.77K | 36.97K | 61.26K | 110.99 | 99.63 | |
| Days payables outstanding | 2.15 | 0.44 | 0.59 | 21.25 | 22.06 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0.81 | 0.9 | |
| Payables turnover | 41.89 | 202.73 | 151.6 | 4.23 | 4.08 | |
| Inventory turnover | 461.96M | 920.39M | 1.43B | 723.21M | 1.61B | |
| ROE | -0.06 | -0.05 | -0.07 | -0.02 | -0.04 | |
| Capex per share | -0.04 | -0.04 | -0.04 | -0.01 | -0.01 |
BLU Frequently Asked Questions
What is BELLUS Health Inc. stock symbol ?
BELLUS Health Inc. is a CA stock , located in Laval of Qc and trading under the symbol BLU
What is BELLUS Health Inc. stock quote today ?
BELLUS Health Inc. stock price is $- today.
Is BELLUS Health Inc. stock public?
Yes, BELLUS Health Inc. is a publicly traded company.
Company Profile
- Volume Average 5.38M
- Market Capitalization 1.87B
- Employee 74
- CEO Mr. Roberto Francesco Bellini
- Headquarters Laval,QC,CA
- IPO Date 2000-10-27
-
Website
https://www.bellushealth.com 
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
